Targeted therapies have unique toxicity profiles. Common adverse events include rash,
diarrhea, hypertension, hypothyroidism, proteinuria, depigmentation, and hepatotoxicity …

Background With the wide application of targeted drug therapies, the relevance of
prognostic and predictive markers in patient selection has become increasingly important …

BACKGROUND Hypertension (HTN) is an established class effect of vascular endothelial
growth factor receptor (VEGFR) inhibition. In the phase 3 Study of (E7080) Lenvatinib in …

Purpose Vascular endothelial growth factor signaling pathway plays a crucial role in
angiogenesis and has become a promising target for cancer drug development. We aimed …

In human patients, drugs that block tumor vessel growth are widely used to treat a variety of
cancer types. Many rigorous phase 3 clinical trials have demonstrated significant survival …

Introduction Arterial hypertension and proteinuria are common side effects of antiangiogenic
treatment and might represent a biomarker of response in patients with glioblastoma. The …

Given prior studies that suggest the use of angiotensin system inhibitors (ASIs) is associated
with prolonged overall survival (OS) in glioblastoma (GBM) patients, we evaluated the effect …

Purpose Angiogenesis plays a key role in glioblastoma, but most anti-angiogenic therapy
trials have failed to change the poor outcome of this disease. Despite this, and because …

Targeted treatments have distinctive side effects: dermatologic problems (rash, hand-food
skin reaction, skin/hair whitening), endocrine dysfunction (hyperglycemia, hypothyroidism …

Gliomas are the most common primary intrinsic tumor in the brain and are classified as low-
or high-grade according to the World Health Organization (WHO). Patients with high-grade …